UroGen Pharma Ltd. (URGN)

UroGen Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-126.87	-102.24	-109.78	-110.82	-128.48
Depreciation & Amortization	1.19	1.71	1.82	1.77	2.04
Other Amortization	-	-	1.75	-	-
Loss (Gain) From Sale of Investments	-2.89	-1.03	-0.5	0.48	0.44
Stock-Based Compensation	13.11	9.34	10.58	23.11	28.03
Other Operating Activities	13.77	12.52	13.75	13.67	-1.54
Change in Accounts Receivable	-4.86	-2.74	-0.99	-4.67	-7.05
Change in Inventory	-3.55	-1.35	-0.36	-2.87	-1.96
Change in Accounts Payable	10.89	4.16	0.28	2	-1.25
Change in Income Taxes	0.6	0.18	0.18	0.13	2.72
Change in Other Net Operating Assets	1.86	3.09	-4.29	-7.69	1.17
Operating Cash Flow	-96.77	-76.38	-87.56	-84.89	-105.89
Capital Expenditures	-0.3	-0.19	-0.25	-0.75	-1.22
Investment in Securities	-20.32	-0.76	1.31	4.82	94.45
Investing Cash Flow	-20.61	-0.95	1.06	4.07	93.24
Long-Term Debt Issued	24.49	-	95.78	-	-
Net Debt Issued (Repaid)	24.49	-	95.78	-	-
Issuance of Common Stock	151.49	68.23	1.51	72.46	16.59
Other Financing Activities	18.64	48.7	-0.16	-0.14	-0.07
Financing Cash Flow	194.62	116.93	97.13	72.32	16.53
Net Cash Flow	77.24	39.6	10.64	-8.5	3.88
Free Cash Flow	-97.06	-76.57	-87.81	-85.64	-107.1
Free Cash Flow Margin	-107.37%	-92.57%	-136.45%	-178.27%	-907.71%
Free Cash Flow Per Share	-2.26	-2.66	-3.85	-3.83	-4.92
Levered Free Cash Flow	-46.83	-35.16	-42.79	-44.14	-55.94
Unlevered Free Cash Flow	-39.01	-25.96	-39.27	-44.14	-55.94
Change in Net Working Capital	-6.79	-4.14	2.01	10.59	9.71

Updated Mar 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q